Karyopharm Therapeutics Inc KPTI.OQ KPTI.O is expected to show a rise in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025
The Newton Massachusetts-based company is expected to report a 6.4% increase in revenue to $35.242 million from $33.13 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Karyopharm Therapeutics Inc is for a loss of $4.18 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $54.00, above its last closing price of $6.76.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -4.32 | -3.92 | -3.60 | Beat | 8.2 |
Sep. 30 2024 | -3.76 | -3.94 | -3.90 | Beat | 1.1 |
Jun. 30 2024 | -4.31 | -4.48 | 2.25 | Beat | 150.2 |
Mar. 31 2024 | -4.93 | -5.01 | -4.80 | Beat | 4.2 |
Dec. 31 2023 | -4.68 | -4.65 | -5.40 | Missed | -16.2 |
Sep. 30 2023 | -4.26 | -4.20 | -4.50 | Missed | -7.1 |
Jun. 30 2023 | -5.26 | -5.13 | -4.35 | Beat | 15.3 |
Mar. 31 2023 | -5.43 | -5.52 | -4.50 | Beat | 18.5 |
This summary was machine generated May 2 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。